XML 34 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Equity
3 Months Ended
Mar. 31, 2013
Equity [Abstract]  
Equity
7. Equity
 
Warrants
 
BioTime has issued warrants to purchase its common shares as payments for services and in connection to certain business acquisitions.  At March 31, 2013, 816,612 warrants to purchase common shares with a weighted average exercise price of $8.41 and a weighted average remaining contractual life of 1.5 years were outstanding.  At December 31, 2012, 556,613 warrants to purchase common shares with a weighted average exercise price of $10.00 and a weighted average remaining contractual life of 1.32 years were outstanding.
 
Preferred Shares
 
BioTime is authorized to issue 1,000,000 shares of preferred stock.  The preferred shares may be issued in one or more series as the board of directors may by resolution determine.  The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, references, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares.  The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series.
 
As of March 31, 2013 BioTime has no issued and outstanding preferred shares.
 
Common Shares
 
BioTime is authorized to issue 75,000,000 common shares with no par value.  As of March 31, 2013, BioTime had issued 54,912,781 common shares and outstanding 52,551,813 common shares.
 
During the three months ended March 31, 2013, no options or warrants were exercised.

During the three months ended March 31, 2013 and 2012, BioTime recognized stock-based compensation expenses of $691,946 and $473,434, respectively, due to stock options granted to employees and directors.  During the three months ended March 31, 2013 and 2012, BioTime granted 1,090,000 and 105,000 options, respectively, under its 2012 Equity Incentive Plan and 2002 Stock Option Plan.